Artificial intelligence has evolved from an auxiliary research tool into a foundational disruptive force reshaping the entire biopharma value chain, covering target identification, novel molecule design, clinical trial optimization, manufacturing and regulatory compliance. For decades, the drug development model built around physical laboratories has suffered from endemic inefficiency, yet a 2026 April industry workshop themed “AI in Pharma & Biotech” solidified a universal industry consensus: machine learning and deep learning-powered R&D platforms drastically slash development timelines and cut staggering trial-and-error costs, marking a paradigm shift for global drug research.
The pharmaceutical sector has long been trapped in a punishing cycle of massive investment, glacial output and low clinical success rates. Global drug developers pour hundreds of billions of US dollars into annual R&D, yet newly approved therapies have flatlined at just 45 to 50 per year for over a decade. Conventional drug development takes more than 10 years on average and costs between $1 billion and $2 billion per approved medicine; over 90% of candidates entering Phase I trials ultimately fail to reach commercialization, leaving billions in sunk capital unrecovered. Recent leaps in computing power, massive multi-omics biological datasets and generative AI have unlocked a viable solution to this structural industry pain point.
Across the sector, companies have adopted divergent AI deployment strategies. Legacy large-cap pharma players including Bayer, AstraZeneca and Eli Lilly are pouring capital to build proprietary in-house AI research infrastructure. AI-native biotech startups such as Insitro, Insilico Medicine and Formation Bio leverage custom algorithm models to tackle niche research segments. The Chan Zuckerberg Biohub has doubled down on AI-driven virtual biology simulations, replacing countless wet-lab experiments with digital cell modeling to accelerate cures for hard-to-treat diseases. Industry insiders widely agree that core drug discovery operations will gradually migrate from brick-and-mortar labs to digital AI platforms, opening a trillion-dollar industrial transformation window.
Two US-listed firms stand out as representative blueprints of AI biotech commercialization: Eli Lilly (LLY), a century-old pharma giant integrating AI across its full pipeline, and Twist Bioscience (TWST), a synthetic DNA infrastructure provider partnering with cloud tech giants to supply foundational AI research materials. Their opposing growth frameworks, financial profiles and valuation volatility lay bare the two dominant investment narratives defining AI-powered drug development.
Founded in the 1870s, Eli Lilly ranks among the world’s most diversified pharmaceutical leaders, anchored by robust franchises in diabetes, weight-loss metabolism, oncology and autoimmune disorders. The firm’s core strategy hinges on fully embedding AI throughout its end-to-end drug development workflow via capital-intensive, pipeline-wide internal computing and algorithm systems, delivering steady, low-volatility long-term growth characteristic of established big pharma.
Lilly runs two landmark AI collaboration streams to supercharge its lab operations. It partners with OpenAI to advance target prediction and novel molecular screening, while co-developing a dedicated AI innovation lab with NVIDIA to deploy pharma-specific supercomputing clusters. This elite computational infrastructure condenses molecular screening cycles that once spanned years down to mere months. The drugmaker also maintains deep ties with AI biotech specialists like Insitro, integrating cutting-edge machine learning to refine pharmacology and toxicology forecasting, cutting animal testing expenditure and lowering late-stage clinical failure risks. The company’s trillion-dollar market cap signals Wall Street’s full conviction in AI’s ability to overhaul traditional drug research.
AI-driven operational gains are already reflected in explosive financial performance. In Q1 2026, Lilly’s revenue surged 56% year-over-year to $19.8 billion, while net income rocketed 168% to $7.4 billion—profit growth running three times faster than top-line expansion, a remarkable efficiency milestone for a large-cap pharmaceutical enterprise. As of June 17, Lilly shares traded near $1,120, perched close to the upper bound of its 52-week range of $623.78–$1,182.73. The stock has climbed 36% over the past 12 months and more than 400% across the last five years, cementing its status as a core, reliable holding in healthcare portfolios.
Beyond lab-based AI innovation, newly approved oral weight-loss pill Foundayo represents Lilly’s next major growth catalyst. Unlike injectable weight-loss treatments, the oral formulation can be administered at any time of day, removing critical access barriers and unlocking a far broader patient population. Paired with Lilly’s established global manufacturing capacity, Foundayo is poised to deliver sustained revenue expansion alongside its AI-discovered drug pipeline, creating a dual growth engine. Backed by mature global commercial networks, proprietary clinical datasets and self-built AI computing capacity, Lilly operates a closed loop linking digital research and pharmaceutical sales, positioning it as a conservative, long-duration play within the AI biotech sector.
Twist Bioscience, founded in 2013, operates on a fundamentally different vertical model compared to Lilly’s fully integrated pharma blueprint. Positioned as an upstream foundational supplier for biotech research, the firm specializes in custom synthetic DNA manufacturing and capitalizes on cloud-based AI drug development trends by supplying core lab materials to the broader industry, following an asset-light platform model defined by high growth upside paired with elevated volatility.
Twist’s core value proposition lies in supplying standardized, cost-effective synthetic DNA to global pharmaceutical firms and AI biotech startups, supporting upstream research workflows including target validation, molecular engineering and gene screening. The company has secured a key partnership with Amazon (AMZN) AWS’s Bio Discovery cloud platform, emerging as a primary physical lab collaborator for the tech giant’s cloud-hosted drug development ecosystem. Scientists design therapeutic molecules and run target simulations via AI tools on the AWS cloud, and all synthetic DNA required to translate those digital designs into wet-lab experiments is sourced from Twist, letting the firm capture rising industry-wide spending on AI research as incremental order volume.
Financially, Twist boasts an impressive streak of 13 consecutive quarters of year-over-year revenue expansion. In fiscal Q2 2026, top-line revenue rose 19% to $110.7 million, demonstrating durable demand for its core synthetic DNA products. However, the firm remains in an investment-heavy phase focused on technological scaling and ecosystem expansion. A one-time $7.2 million legal settlement widened its net loss to $44 million, up from $39.3 million in the same period last year, and the company has yet to achieve consistent profitability amid persistent operational investment pressures.
Its stock performance mirrors its high-risk, high-reward profile: Twist’s share price has jumped more than 136% in the trailing 12 months, delivering sharp short-term upside, yet the stock has lost 26% over the past five years, with far greater price swings than established pharmaceutical peers. Unlike Lilly, Twist does not develop or commercialize proprietary drugs; it generates steady recurring revenue from upstream lab consumables, benefiting from broad industry AI R&D spending without capturing the outsized windfalls of a blockbuster approved therapy. Its long-term growth ceiling is directly tied to downstream drug developers’ research budgets.
The investment narrative around AI-powered pharmaceuticals is undergoing a critical rotation across capital markets. The first wave of sector gains favored firms supplying underlying infrastructure—computing hardware, algorithm software and lab research tools. The next leg of value creation will accrue to companies that leverage AI to advance proprietary drug pipelines through clinical trials and into commercial launch.
Lilly and Twist occupy opposite ends of the biotech value chain, embodying two distinct winning models: integrated drug developers that capture full profits from internally discovered therapies, and upstream material vendors that share incremental growth across the entire industry. The two assets cater to investors with vastly different risk tolerances and illustrate the two primary viable frameworks for AI’s industrial rollout within biotech.
AI penetration across pharmaceutical research remains in early stages, and neither stock guarantees positive returns—upside potential carries material risks including unproven AI technology, clinical trial setbacks and intensifying industry competition. Still, the contrasting operational journeys of Eli Lilly and Twist Bioscience offer a clear roadmap for market participants seeking to evaluate the long-term fusion of artificial intelligence and life sciences.
